Due to the fact that TP53 mutations occur in the early stage during carcinogenesis, the lead time of TP53 AABs to diagnosis ovarian cancer is longer than with traditional detection methods, with an average elevation of 8.1 months and 9.2 months compared with a detection by CA125 alone or the ROCA, respectively [101]. This evidence concerns the gene TP53 and ovarian carcinoma.